Quantcast

Latest Clostridium difficile Stories

2014-07-07 16:23:01

LONDON, July 7, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:MarketVIEW: Clostridium difficile vaccines http://www.reportbuyer.com/pharma_healthcare/therapeutic/marketview_clostridium_difficile_vaccines.htmlClostridium difficile (C.diff) is a Gram-positive bacterium, which in vulnerable hospitalized patients can cause gastrointestinal infections (CDI). Outcomes range from mild uncomplicated diarrhea to severe-complicated disease where patients...

2014-07-07 12:28:38

Company's Breakthrough Innovation to Enable First Therapeutics for Microbiome-based Diseases CAMBRIDGE, Mass., July 7, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pharmaceutical composition patent application that covers its lead product candidate, SER-109, which is currently...

2014-06-30 08:29:30

-- Company Expects to Initiate C. difficile Clinical Trials in 2014 -- ROCKVILLE, Md., June 30, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating...

2014-06-19 04:21:30

LAUSANNE, Switzerland, June 19, 2014 /PRNewswire/ -- Debiopharm Group(TM)(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known...

2014-06-18 16:26:41

GERMANTOWN, Maryland, and HILDEN, Germany, June 18, 2014 /PRNewswire/ -- - Assay offers faster quantification of CMV DNA levels in patient samples - Up to 60% of all transplant patients are repeatedly tested for CMV viral load to help avoid potentially life-threatening conditions caused by this virus - PMA approval of artus(R) CMV RGQ MDx Kit adds further value to the QIAsymphony modular family of automated instruments as the...

2014-06-17 12:37:42

American Society for Microbiology Fecal microbiota transplantation --- the process of delivering stool bacteria from a healthy donor to a patient suffering from intestinal infection with the bacterium Clostridium difficile --- works by restoring healthy bacteria and functioning to the recipient's gut, according to a study published this week in mBio®, the online open-access journal of the American Society for Microbiology. The study provides insight into the structural and potential...

2014-06-10 04:22:10

-- Study to Define Impact of Beta-Lactam Antibiotics on Intestinal Bacteria -- ROCKVILLE, Md. and PARIS, June 10, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, today announced...

2014-06-09 08:28:32

GLASGOW, Scotland, June 9, 2014 /PRNewswire/ -- Grant to help fund Phase I trial with lead candidate oral MGB-BP-3 for Clostridium difficile MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives, announces today that it has been awarded a GBP1.3 million conditional grant from the Technology Strategy Board, the UK's innovation agency, under its Biomedical Catalyst programme. The grant will...

2014-06-05 08:28:17

Foundation for highly acclaimed "Safe Hands" anti-infection program WOLVERHAMPTON, West Midlands, U.K., June 5, 2014 /PRNewswire/ -- New Cross Hospital, part of The Royal Wolverhampton NHS Trust, today announced a milestone of one million hand hygiene observations using TeleTracking Technologies, Inc.'s automated hand hygiene sensor as part of the 'Safe Hands' program. This compares to just 600 visual observations over the same time period. Safe Hands is a government-funded...

2014-06-02 04:20:57

GLASGOW, Scotland, June 2, 2014 /PRNewswire/ -- MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives, announces today that Dr Stephanie Dancer, an internationally renowned medical microbiologist, has joined its scientific advisory board (SAB). She will help oversee the development of MGB Biopharma's lead antibiotic candidate, MGB-BP-3. An oral formulation of MGB-BP-3 is ready to enter Phase I development for Clostridium difficile, and an iv...


Latest Clostridium difficile Reference Libraries

0_9f897835bb09adc2a84fda23893d87f8
2011-04-15 13:50:01

Clostridium difficile, also known as "CDF/cdf", or "C. diff", is a Gram-positive bacteria of the genus Clostridium that causes severe diarrhea and other intestinal disease when competing bacteria in the gut flora are wiped out by antibiotics. They are anaerobic, spore-forming rods and is the most serious cause of antibiotic-associated diarrhea and potentially to pseudomembranous colitis. C. difficile bacteria naturally resides in the gut of a small percentage of the adult population. Others...

More Articles (1 articles) »
Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.